Statins to Prevent Cancer Associated Blood Clots
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4000 participants.
Also called NCT07303816
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 4,000 participants
- Registry
-
NCT07303816
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07303816. Randomized; triple masking; primary purpose prevention. Start 2026-06-11 (actual); primary completion 2031-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Statins to Prevent Cancer Associated Blood Clots
- Acronym
- STAT-CAT
- Condition
- Venous Thromboembolism
- Condition
- Cancer
- Condition
- Cardiovascular Events
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Placebo Drug
- Lead sponsor
- Brigham and Women's Hospital
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Dana-Farber/Brigham and Women's Cancer Center
Record details
- Record id
cardio:ct-nct07303816- Content hash
1a45b5b0716013e06df25de53a3a6b2bbd93435f32500f12d6f7b64682f757df